# Noema Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/noema-pharma

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.noemapharma.com
- Total disclosed funding: $170M
- Latest round: Series B (Dec 11, 2024)
- Investors on record: 9

## About

Headquartered in Basel, Switzerland, Noema Pharma AG focuses on developing innovative therapeutic solutions for central nervous system conditions, particularly targeting severe neurological disorders.Noema Pharma AG, established in 2019, specializes in the development of therapies for central nervous system conditions. The company was founded by George Garibaldi and Luigi Costa, with Ilise Lombardo serving as CEO. Noema has successfully completed 4 funding deals, most recently raising CHF 103.000 mn in a SERIES B round on December 11, 2024, with participation from investors including Forbion, Gilde Healthcare Partners, and Invus.Noema Pharma specializes in developing innovative therapies aimed at addressing various central nervous system (CNS)-mediated conditions. The company's primary products include three mid-clinical-stage therapeutics that target persistent seizures related to Tuberous Sclerosis Complex, severe pain from Trigeminal Neuralgia, and involuntary tics associated with Tourette Syndrome. Additionally, they focus on Childhood Onset Fluency Disorder and menopausal symptoms like vasomotor symptoms (VMS). Noema Pharma aims to address both orphan and larger patient populations, reflecting a strategy to meet specialized healthcare needs.Noema Pharma's revenue model is built around partnerships and collaborations aimed at commercializing its therapeutics. The company engages directly with healthcare organizations to deliver its mid-clinical-stage products to patients post-clinical trials and approvals. Revenue generation primarily occurs through the sales of therapeutics, which are structured around collaborations with healthcare providers, potentially involving direct-to-consumer initiatives or partnerships with hospitals and clinics.In December 2024, Noema Pharma AG raised CHF 130.000 mn in SERIES B funding led by EQT Life Sciences, with participation from multiple investors. The funding will be utilized to advance the development of clinical-stage assets, including basimglurant (NOE-101), gemlapodect (NOE-105), and NOE-115. Noema Pharma plans to launch new products designed to address significant medical needs and expand into diverse geographic regions, although specific markets and release dates have not been disclosed.

## Funding rounds

- Series B, Dec 11, 2024 — Sofinnova Partners, Polaris Partners, EQT Life Sciences, Gilde Healthcare, Invus [DUP], Forbion, Jeito Capital, UPMC Enterprises
- Series B, Mar 7, 2023, $110M — Sofinnova Partners, Polaris Partners, Gilde Healthcare, Invus [DUP], Forbion, UPMC Enterprises, Jeito Capital
- Series A, Dec 1, 2020, $61M — Sofinnova Partners, Polaris Partners, Gilde Healthcare, BioMed Partners, Invus [DUP]
- Seed, Jun 1, 2019 — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Invus [DUP] — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series B
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B